跳至主要内容
临床试验/JPRN-jRCT2080220744
JPRN-jRCT2080220744未知2 期

Phase II study of KW-0761 in subjects with CCR4-positive adult T-cell leukemia-lymphoma

Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 25 人开始时间: 2009年6月9日最近更新:

试验速览

阶段
2 期
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1: Positive for serum anti-HTLV-I antibody
  • 2: Acute-, lymphoma-, or chronic-type with poor prognostic factors specified in the past
  • 3: Positive for CCR4
  • 4: Relapsed subject after the response (CR, CRu or PR) in the last previous chemotherapy
  • 5: Received at least one prior chemotherapy
  • 6: Only after 4 weeks had elapsed since the most recent treatment 4 weeks
  • 7: PS of 0 to 2
  • 8: Negative for HBs antigen and for HBV-DNA by a real-time PCR

排除标准

  • 1: A history of transplantation such as hematopoietic stem cells
  • 2: Positive for HCV antibody or HIV antibody
  • 3: Active multiple cancers at the time of starting this clinical study
  • 4: Previous history of allergic reactions after receiving antibody products
  • 5: Requiring continuous systemic treatment with a steroid
  • 6: Requiring such radiotherapy after starting this clinical study
  • 7: Treated with any investigational drug other than KW-0761 within three months

研究者

发起方
Kyowa Hakko Kirin Co., Ltd.

相似试验

Phase II study of KW-0761 | 临床试验